Literature DB >> 31069999

Current status of hepatopulmonary syndrome in liver transplantation in Japan: a Japanese multicenter analysis.

Yoshihito Kotera1, Hiroto Egawa1, Satoshi Ogata1, Satoshi Teramukai2, Toshimi Kaido3, Ken Shirabe4, Akinobu Taketomi5, Yasutugu Takada6, Masakazu Yamamoto1, Hiroki Yamaue7.   

Abstract

BACKGROUND: Hepatopulmonary syndrome (HPS) negatively affects the outcomes of deceased donor liver transplantation (LT).
METHODS: We retrospectively reviewed the clinical records of patients with HPS who underwent LT and studied the impact of risk factors on clinical outcomes to determine strategies to overcome complications. Patients with symptoms of hypo-oxygenemia and a shunt ratio >15% on 99mTc-MAA lung perfusion scintigraphy were defined as having HPS.
RESULTS: Forty-eight patients in 10 centers were enrolled. Diseases included biliary atresia, liver cirrhosis, non-alcoholic steatohepatitis, congenital hepatic fibrosis, and others. The length of ICU stay was 2-170 days. The respirator was used for 41.6% of patients on post-operative day (POD) 3 and 20.8% on POD 14. The patient survival rate was 87% at 1 year and 82% at 5 years. The causes of hospital mortality were sepsis, thrombotic microangiopathy, intracranial bleeding, pulmonary fibrosis, and transplant rejection. An amount of shunt ratio prior to LT was a significant risk factor for hospital mortality. Hypoxia from POD 3 to POD 14 was a risk factor for biliary stenosis. The shunt ratio of all surviving patients significantly improved.
CONCLUSION: Although LT is feasible for patients with HPS, early transplantation and avoiding hypo-oxygenemia immediately after transplantation are important.
© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Hepatopulmonary syndrome; Liver transplantation

Mesh:

Year:  2019        PMID: 31069999     DOI: 10.1002/jhbp.632

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  2 in total

1.  Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study.

Authors:  Nuria Mendoza; Eva Rivas; Roberto Rodriguez-Roisin; Tamara Garcia; Miquel Bruguera; Alvar Agusti; Rosa Faner
Journal:  PLoS One       Date:  2021-02-25       Impact factor: 3.240

2.  Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum.

Authors:  Zakiyah Kadry; Eric Schaefer; Karen Krok; Alison Faust; Jonathan Gibson Stine; Ian Roy Schreibman; Dmitri Bezinover; Thomas Roberts Riley
Journal:  JHEP Rep       Date:  2021-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.